Abstract:Key PointsMuscle wasting is a debilitating condition that develops with ageing and more rapidly with inactivity (bed rest) and in various systemic diseases (for example, cancer, renal failure, chronic obstructive pulmonary disease, sepsis, HIV and trauma). Fibre atrophy primarily results from an acceleration of protein degradation, often combined with reduced protein synthesis. Treatments that prevent this activation of proteolysis or increase protein synthesis offer considerable promise to combat this debilitating process.Various types of rapid muscle wasting develop through a common transcriptional programme involving the induction of a set of atrophy-related genes (atrogenes) by forkhead box protein O (FOXO) transcription factors and reduced signalling by the PI3K–AKT–mTOR pathway.The resulting muscle weakness is a consequence of the degradation of myofibrils, which is catalysed by ubiquitin ligases that target different components of the contractile apparatus for proteasomal degradation. By contrast, the loss of endurance results from the breakdown of mitochondria via autophagy.Myostatin, an autocrine inhibitor of normal muscle growth, and its circulating homologue activin A, also trigger muscle protein loss in various catabolic states via the activation of SMAD2 and SMAD3, which function together with FOXO transcription factors.Antibodies against myostatin or activin A, or agents that block their receptor — activin A receptor, type IIB (ActRIIB) — in muscle could be a promising approach to combat muscle loss caused by cancer-associated cachexia, renal failure and ageing. Indeed, these treatments helped to preserve muscle and prolong longevity in tumour-bearing mice, and several of these treatments are currently in clinical trials.Glucocorticoids and various circulating inflammatory mediators, such as tumour necrosis factor-α (TNFα) and interleukin-6 (IL-6), have also been implicated in excessive muscle proteolysis in cachexia, but their roles in different catabolic states remain uncertain and controversial.Recent studies have increased our understanding of the biochemical mechanisms of atrophy and have identified many intracellular proteins that are crucial in muscle wasting (for example, SMADs, tripartate motif-containing protein 32 (TRIM32), nuclear factor-κB (NF-κB)) or that combat this process (for example, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), sirtuin1 (SIRT1) and JUNB). Their manipulation by small molecules offers many opportunities for the rational design of new treatments for this condition.

Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action

Skeletal muscle atrophy: From mechanisms to treatments

Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs

Potential Therapeutic Strategies for Skeletal Muscle Atrophy

Muscle wasting in disease: molecular mechanisms and promising therapies

Muscle wasting in ageing and chronic illness

Muscle Wasting Diseases: Novel Targets and Treatments

15-PGDH: a Potential Target for the Treatment of Muscle Atrophy

Emerging Strategies Targeting Catabolic Muscle Stress Relief

Role of Pro-inflammatory Cytokines in Regulation of Skeletal Muscle Metabolism: A Systematic Review

Nutritional Strategies for Muscle Atrophy: Current Evidence and Underlying Mechanisms

Cellular and molecular mechanism of skeletal muscle atrophy and anti-atrophic muscle training

The clinical relevance and mechanism of skeletal muscle wasting

Nutraceuticals In The Prevention And Treatment Of The Muscle Atrophy

The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation

Cellular and molecular mechanisms of muscle atrophy

Muscle Atrophy Induced by Mechanical Unloading: Mechanisms and Potential Countermeasures

Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training

Pharmacologic approaches to prevent skeletal muscle atrophy after spinal cord injury

Mechanisms underlying the anti-wasting effect of l-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies

Micro(RNA)-managing muscle wasting